Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Biogen Idec and Elan Corporation, plc today announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for TYSABRI in the European Union.

18 Apr 2011

New study finds apparent gaps in restaurant staff's knowledge of food allergy

A new study published in Clinical & Experimental Allergy reveals that there is no association between a restaurant worker's knowledge of food allergy and his or her confidence in being able to provide a safe meal to a food allergic customer.

16 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Milk allergy successfully treated with Xolair

A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.

22 Mar 2011

Researchers to develop house dust mite allergy vaccine that can cure asthma

Monash University researchers are working on a vaccine that could completely cure asthma brought on by house dust mite allergies.

22 Mar 2011

AANMA survey details the impact of asthma and allergies on patients and their families

Today Allergy & Asthma Network Mothers of Asthmatics released a first-of-its-kind survey detailing the impact of asthma and allergies on the people who cope with it every day.

18 Mar 2011

Peanut allergy has a genetic link: Study

A new study suggests that children with a certain gene defect are more likely to develop a peanut allergy. They studied the effect of changes in the gene filaggrin, which helps the skin block out allergens. They noted what has been seen before – the changes in the gene reduce the effectiveness of the barrier, increasing the risk for eczema and asthma.

14 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Grifols receives FDA approval for Alphanate to treat vCJD

Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it received approval from the US Food and Drug Administration for revised labeling for Alphanate Antihemophilic Factor/von Willebrand Factor Complex indicating that certain manufacturing steps have been shown to reduce the infectivity of a experimental TSE agent that is a model for variant Creutzfeldt Jakob Disease.

5 Mar 2011

Scientists devise new on-line calculator to predict food allergies in children

An on-line calculator that predicts, within seconds, the presence of the three major food allergies in children has been developed by researchers at University College Cork.

2 Mar 2011

Experts offer myth-busting advice to fight against spring allergies

Millions of Americans sneeze and wheeze March through June when they use misinformation to manage their spring allergies.

27 Feb 2011

AMAG fourth quarter total revenues increase to $17.2 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2010.

25 Feb 2011

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

25 Feb 2011

New guidelines recommend routine use of allergy tests to improve quality of care in children

The first guidelines for food allergy in children and young people issued by NICE, National Institute for health and Clinical Excellence, recommend routine use of allergy tests in NHS primary care and community settings to confirm suspected food allergy.

24 Feb 2011

ASC launches ACT NOW to offer support, education about asthma and respiratory allergies

In response to increasing public enquiries for information on respiratory allergies, the Asthma Society of Canada announced today the launch of Allergies Count Too, NOW a program that will fill the gap in allergy education and provide critical information to Canadians.

9 Feb 2011

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.

9 Feb 2011

Anaphylaxis News and Research

Further Reading

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

New study finds apparent gaps in restaurant staff's knowledge of food allergy

Lupin grants Salix exclusive worldwide rights to rifaximin

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Merck enters definitive agreement to acquire Inspire

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Milk allergy successfully treated with Xolair

Researchers to develop house dust mite allergy vaccine that can cure asthma

AANMA survey details the impact of asthma and allergies on patients and their families

Peanut allergy has a genetic link: Study

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Grifols receives FDA approval for Alphanate to treat vCJD

Scientists devise new on-line calculator to predict food allergies in children

Experts offer myth-busting advice to fight against spring allergies

AMAG fourth quarter total revenues increase to $17.2 million

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

New guidelines recommend routine use of allergy tests to improve quality of care in children

ASC launches ACT NOW to offer support, education about asthma and respiratory allergies

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News